Brookdale Shares Down 4.9% Despite Q1 Earnings Meeting Estimates
BKD continues to witness growth in revenue per available unit (RevPAR). It increases its EBITDA range for 2025.
Brookdale Senior Living, Inc. (BKD) Q1 2025 Earnings Call Transcript
Brookdale Senior Living, Inc. (NYSE:BKD ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Jessica Hazel – Vice President, Investor Relations Denise Warren – Interim Chief Executive Officer and Chairman Dawn Kussow – Executive Vice President and Chief Financial Officer Chad White – Executive Vice President-General Counsel and Secretary Conference Call Participants Ben Hendrix – RBC Brian Tanquilut – Jefferies Andrew Mok – Barclays Tao Qiu – Macquarie Joanna Gajuk – Bank of America Josh Raskin – Nephron Research Operator Good morning. My name is Audra and I will be your conference operator today.
Brookdale Senior Living (BKD) Reports Q1 Loss, Lags Revenue Estimates
Brookdale Senior Living (BKD) came out with a quarterly loss of $0.11 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.13 per share a year ago.
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?
Here is how Brookdale Senior Living (BKD) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Take the Zacks Approach to Beat the Markets: Pro-Dex, Brookdale Senior Living, Coca-Cola in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year?
Here is how Brookdale Senior Living (BKD) and Claritev Corporation (CTEV) have performed compared to their sector so far this year.
Why Fast-paced Mover Brookdale (BKD) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Brookdale (BKD) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Wall Street Analysts See a 25.3% Upside in Brookdale (BKD): Can the Stock Really Move This High?
The consensus price target hints at a 25.3% upside potential for Brookdale (BKD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Should Value Investors Buy Brookdale Senior Living (BKD) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?
Here is how Brookdale Senior Living (BKD) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Despite Fast-paced Momentum, Brookdale (BKD) Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Brookdale (BKD) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Here's What Brookdale's Occupancy Growth Story Tells Us
BKD is likely to have witnessed 40 straight months of year-over-year increases in weighted average occupancy.
